| P50 | author | Martha Campbell-Thompson | Q37381204 |
| P2093 | author name string | Sihong Song | |
| | Terence R Flotte | |
| | Kirsten Erger | |
| | Thomas J Conlon | |
| | Travis Cossette | |
| | Young-Kook Choi | |
| | James Crawford | |
| | Tracy Clarke | |
| | Marda Scott-Jorgensen | |
| P2860 | cites work | Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 |
| | Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer | Q33802811 |
| | AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 |
| | Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses | Q34353746 |
| | Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle | Q35054512 |
| | Recent developments and current status of gene therapy using viral vectors in the United Kingdom | Q35912224 |
| | Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors | Q36509889 |
| | DNA-dependent PK inhibits adeno-associated virus DNA integration | Q36604872 |
| | Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors | Q40692830 |
| | Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema | Q40797789 |
| | High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. | Q40933793 |
| | A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line | Q40952202 |
| | Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo | Q41894646 |
| | Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects | Q44136395 |
| | Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. | Q44974380 |
| | Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults | Q45676046 |
| | Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors | Q45735547 |
| | Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors | Q45738268 |
| | Detection of infectious adeno-associated virus particles in human cervical biopsies | Q45754547 |
| | Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors | Q45872692 |
| | Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes | Q46455576 |
| | Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase | Q68090902 |
| | Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin | Q68834674 |
| P433 | issue | 5 | |
| P921 | main subject | vector-borne disease | Q2083837 |
| P304 | page(s) | 867-875 | |
| P577 | publication date | 2005-08-08 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector | |
| P478 | volume | 12 | |